SCHEDULE: Vanguard Group Amends Intellia Therapeutics Stake

The Vanguard Group updated its beneficial ownership in Intellia Therapeutics Inc., reporting an 11.23% stake as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 13,010,001 shares of Intellia Therapeutics Inc. Common Stock.
• This represents 11.23% of the class of securities.
• The Vanguard Group holds sole voting power over 0 shares and shared voting power over 864,210 shares.
• The Vanguard Group holds sole dispositive power over 0 shares and shared dispositive power over 13,010,001 shares.
• An internal realignment occurred at The Vanguard Group, Inc. on January 12, 2026, where it ceased performing portfolio management services or administering proxy voting.
• Following the realignment, certain subsidiaries or business divisions of Vanguard Group, Inc. are expected to report beneficial ownership separately (on a disaggregated basis).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of a significant passive institutional ownership stake, with no direct implications for Intellia's operational performance or strategic direction.

Positives

• The Vanguard Group, a major institutional investor, maintains a significant 11.23% stake in Intellia Therapeutics Inc., indicating continued institutional interest in the company.

Future Outlook

The filing indicates that following an internal realignment on January 12, 2026, The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions will report beneficial ownership separately from The Vanguard Group, Inc. in the future.

Industry Context

StockSavvy.ai notes that large institutional holdings like The Vanguard Group's in Intellia Therapeutics Inc. are typical for publicly traded biotechnology companies, reflecting broad market index tracking or diversified fund investments rather than a specific strategic move. The internal realignment within Vanguard is an operational change for the investment firm itself, not directly related to Intellia's industry position.

Stakeholder Impact

• Shareholders of Intellia Therapeutics Inc. are informed of The Vanguard Group's continued significant passive ownership stake, which may be viewed as a sign of institutional confidence or inclusion in broad market indices.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. are expected to report beneficial ownership separately from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Key Dates

Keywords

Intellia Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, equity stake